Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 126   

Articles published

NVO 54.74 -0.03 (-0.06%)
price chart
Top Healthcare Stocks for 2015: Novo Nordisk A/S (ADR) (NYSE:NVO), Hologic ...
The most recent price of Novo Nordisk A/S (ADR) (NYSE:NVO), is now at a discount to the 12-month high of $58.21 hit on Jun 11, 2015.
Novo Nordisk To Go Ahead With Russian Investment
The world's largest insulin-maker, Novo Nordisk A/S (ADR) (NYSE:NVO) is going ahead with its investment plans for Russia, even after the ruble's drastic fall.
CHMP Gives Positive Opinion On Novo Nordisk's Obesity Drug Saxenda
Yesterday Novo Nordisk A/S (ADR) (NYSE:NVO) said that it has received a positive verdict from the Committee for Medicinal Products for Human Use (CHMP), for its obesity drug Saxenda.
Conquering Hemophilia: Novo Nordisk Reports Encouraging Data From Phase ...
Danish healthcare giant Novo Nordisk A/S (ADR) (NYSE: NVO) has developed NovoEight for the treatment and prevention of bleeding in patients with haemophilia A. NovoEight, which has already been launched in 11 countries including in the U.S.
McDonald's Corporation (MCD), Novo Nordisk A/S (ADR) (NVO), Colgate ...
Another major hedge fund that recently disclosed its long equity positions for the second quarter of 2014 is Jim Simons' Renaissance Technologies, one of the best performing firms in the sector.
Novo Nordisk And Eli Lilly Battling To Win GLP-1 Drug Market
Diabetes patients have a multitude of therapy options available, ranging from tablets and insulin therapies to the less common glucagon-like peptide-1 (GLP-1) agonists.
Related articles »  
Novo Nordisk (NVO) Wins FDA Nod For Weight-Loss Injection
Novo Nordisk A/S (ADR) (NYSE:NVO) announced Wednesday that the US Food and Drug Administration (FDA) has approved its experimental weight-loss injection, Saxenda, to treat obesity in adults.
Related articles »  
Sanofi And Novo Nordisk's Basal-Insulin Battle Continues
Sanofi SA (ADR) (SNY) and Novo Nordisk A/S (ADR) (NVO) are the two main players in the ongoing race for developing effective basal insulin therapies for the treatment of diabetes.
Related articles »  
Novo Nordisk A/S (ADR) (NVO): A Company Solving The Global Diabetes Crisis ...
Novo Nordisk A/S (NYSE: NVO) is the undisputed global leader in the diabetes market. The company's impressive product portfolio is home to five of the world's 10 best-selling diabetes medications.
Related articles »  
Sanofi Still Ahead Of Novo Nordisk In Insulin Drug Race
Novo Nordisk A/S (ADR) (NVO) announced yesterday, that its insulin therapy Tresiba, which was in late-stage trials, has proved to be safe and effective for the treatment of type 1 diabetes in children and young adults.
Related articles »